This pathway is particularly interesting since the expression of CD99 in T cells is sought to detect minimal residual disease in acute lymphoblastic leukemia [80]; and some clinical trials propose CD99 as a therapeutic target in AML [52,100]. This evidence concerns the gene CD99 and acute lymphoblastic leukemia.